150 related articles for article (PubMed ID: 10922203)
1. Neoadjuvant interferon alfa-2b treatment in a murine model for metastatic ocular melanoma: a preliminary study.
Dithmar S; Rusciano D; Lynn MJ; Lawson DH; Armstrong CA; Grossniklaus HE
Arch Ophthalmol; 2000 Aug; 118(8):1085-9. PubMed ID: 10922203
[TBL] [Abstract][Full Text] [Related]
2. Interferon alpha 2b decreases hepatic micrometastasis in a murine model of ocular melanoma by activation of intrinsic hepatic natural killer cells.
Yang H; Dithmar S; Grossniklaus HE
Invest Ophthalmol Vis Sci; 2004 Jul; 45(7):2056-64. PubMed ID: 15223777
[TBL] [Abstract][Full Text] [Related]
3. Combined immunologic and anti-angiogenic therapy reduces hepatic micrometastases in a murine ocular melanoma model.
Yang H; Grossniklaus HE
Curr Eye Res; 2006 Jun; 31(6):557-62. PubMed ID: 16769615
[TBL] [Abstract][Full Text] [Related]
4. [Metastatic uveal melanoma. Development of neoadjuvant treatment in animal experiments].
Dithmar S; Adams AW; Rusciano D; Grossniklaus HE
Ophthalmologe; 2001 Aug; 98(8):761-5. PubMed ID: 11552416
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant interferon therapy for patients with uveal melanoma at high risk of metastasis.
Lane AM; Egan KM; Harmon D; Holbrook A; Munzenrider JE; Gragoudas ES
Ophthalmology; 2009 Nov; 116(11):2206-12. PubMed ID: 19744725
[TBL] [Abstract][Full Text] [Related]
6. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial.
Hansson J; Aamdal S; Bastholt L; Brandberg Y; Hernberg M; Nilsson B; Stierner U; von der Maase H;
Lancet Oncol; 2011 Feb; 12(2):144-52. PubMed ID: 21256809
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study.
Grob JJ; Jouary T; Dréno B; Asselineau J; Gutzmer R; Hauschild A; Leccia MT; Landthaler M; Garbe C; Sassolas B; Herbst RA; Guillot B; Chene G; Pehamberger H
Eur J Cancer; 2013 Jan; 49(1):166-74. PubMed ID: 22975216
[TBL] [Abstract][Full Text] [Related]
8. Depletion of NK cell activity results in growth of hepatic micrometastases in a murine ocular melanoma model.
Dithmar SA; Rusciano DA; Armstrong CA; Lynn MJ; Grossniklaus HE
Curr Eye Res; 1999 Nov; 19(5):426-31. PubMed ID: 10520219
[TBL] [Abstract][Full Text] [Related]
9. [Safety and efficacy of interferon alfa-2b in the adjuvant treatment of uveal melanoma].
Richtig E; Langmann G; Schlemmer G; Müllner K; Papaefthymiou G; Bergthaler P; Smolle J
Ophthalmologe; 2006 Jun; 103(6):506-11. PubMed ID: 16763868
[TBL] [Abstract][Full Text] [Related]
10. Recombinant interferon alfa 2b therapy in a patient with metastatic hepatocellular carcinoma.
Yuen MF; Hon C; Hui CK; Siu CW; Lai CL
J Clin Gastroenterol; 2002 Sep; 35(3):272-5. PubMed ID: 12192207
[TBL] [Abstract][Full Text] [Related]
11. Anterior vs posterior intraocular melanoma. Metastatic differences in a murine model.
Grossniklaus HE; Wilson MW; Barron BC; Lynn MJ
Arch Ophthalmol; 1996 Sep; 114(9):1116-20. PubMed ID: 8790099
[TBL] [Abstract][Full Text] [Related]
12. Quality-of-life evaluation in an interferon therapy after radical surgery in cutaneous melanoma patients.
Rataj D; Jankowiak B; Krajewska-Kułak E; Van Damme-Ostapowicz K; Nowecki ZI; Rutkowski P; Niczyporuk W
Cancer Nurs; 2005; 28(3):172-8. PubMed ID: 15915059
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide and interferon alpha 2b in metastatic melanoma stage IV.
Richtig E; Hofmann-Wellenhof R; Pehamberger H; Forstinger Ch; Wolff K; Mischer P; Raml J; Fritsch P; Zelger B; Ratzinger G; Koller J; Lang A; Konrad K; Kindermann-Glebowski E; Seeber A; Steiner A; Fialla R; Pachinger W; Kos C; Klein G; Kehrer H; Kerl H; Ulmer H; Smolle J
Br J Dermatol; 2004 Jul; 151(1):91-8. PubMed ID: 15270876
[TBL] [Abstract][Full Text] [Related]
14. Patient preferences for adjuvant interferon alfa-2b treatment.
Kilbridge KL; Weeks JC; Sober AJ; Haluska FG; Slingluff CL; Atkins MB; Sock DE; Kirkwood JM; Nease RF
J Clin Oncol; 2001 Feb; 19(3):812-23. PubMed ID: 11157035
[TBL] [Abstract][Full Text] [Related]
15. Interferon for melanoma.
Richtig E; Langmann G
Ophthalmology; 2010 Sep; 117(9):1861. PubMed ID: 20816255
[No Abstract] [Full Text] [Related]
16. Low dose adjuvant angiostatin decreases hepatic micrometastasis in murine ocular melanoma model.
Yang H; Akor C; Dithmar S; Grossniklaus HE
Mol Vis; 2004 Dec; 10():987-95. PubMed ID: 15623988
[TBL] [Abstract][Full Text] [Related]
17. Benefit of adjuvant interferon alfa-2b (IFN-α) therapy in melanoma patients with high serum MMP-8 levels.
Vihinen P; Tervahartiala T; Sorsa T; Hansson J; Bastholt L; Aamdal S; Stierner U; Pyrhönen S; Syrjänen K; Lundin J; Hernberg M
Cancer Immunol Immunother; 2015 Feb; 64(2):173-80. PubMed ID: 25319807
[TBL] [Abstract][Full Text] [Related]
18. A new technique for implantation of tissue culture melanoma cells in a murine model of metastatic ocular melanoma.
Dithmar S; Rusciano D; Grossniklaus HE
Melanoma Res; 2000 Feb; 10(1):2-8. PubMed ID: 10711634
[TBL] [Abstract][Full Text] [Related]
19. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
Eggermont AM; Suciu S; MacKie R; Ruka W; Testori A; Kruit W; Punt CJ; Delauney M; Sales F; Groenewegen G; Ruiter DJ; Jagiello I; Stoitchkov K; Keilholz U; Lienard D;
Lancet; 2005 Oct; 366(9492):1189-96. PubMed ID: 16198768
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma.
Yang H; Jager MJ; Grossniklaus HE
Invest Ophthalmol Vis Sci; 2010 Jun; 51(6):2835-42. PubMed ID: 20089875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
